HIV/HBV co-infection increases the morbidity and mortality beyond those caused by either infection alone and there are number of challenges in it’s treatment. Dr Anchalee Avihingsanon (Thai Red Cross AIDS Research Centre, Bangkok, Thailand) joins touchINFECTIOUS DISEASES to discuss the incidence of HIV/HBV co infection as well as the challenges in it’s treatment.
The presentation entitled ‘Week 48 results of a Phase 3 randomized controlled trial of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) vs dolutegravir + emtricitabine/tenofovir Disoproxil Fumarate (DTG+F/TDF) as initial treatment in HIV/HBV-coinfected adults (ALLIANCE)’ was presented at the International AIDS Society (IAS) 29 July – 2 August, 2022.
- What is the incidence of HIV/HBV co infection in adults and what are the challenges in its treatment?
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen.
Share this Video
Related Videos In HIV
Marina Klein, AIDS2022: Global health burden and the elimination of HIV, hepatitis B, and hepatitis C
There are number of challenges in the elimination of the three blood-borne viruses — HIV, hepatitis B (HBV), and hepatitis C (HCV). Treatment advances have been made with the introduction of highly effective antiviral agents into clinical practice, and prevention strategies. However, for worldwide elimination of these viruses, effective vaccines are required. Dr Marina Klein […]
Marina Klein, AIDS2022: Triple elimination of HIV, HCV and HBV
Dr Marina Klein (McGill University Health Centre, Montreal, Canada) joins touchINFECTIOUS DISEASES to discuss triple elimination of three infections (HIV, HBV and HCV) prevalent in low- and middle-income countries. Dr Klein highlights the challenges of transmission of HIV, hepatitis B and hepatitis C. She also looks current therapies for HIV, the elimination of Hepatitis C, […]
Anchalee Avihingsanon, AIDS2022: Interim analysis of the ALLIANCE study in HIV/HBV coinfected adults
The ALLIANCE study is a randomized control trial comparing tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF) in HIV infection coinfected with hepatitis B in adults initiating first-line antiretroviral treatment. Patients were randomized to get either bictegravir/FTC/TAF vs dolutegravir plus FTC and TDF. Dr Anchalee Avihingsanon (Thai Red Cross AIDS Research Centre, Bangkok, Thailand) joins […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!